Related Experiment Videos
Insights
Aspirin, an antiplatelet agent, is recommended for widespread use in high-risk patients to reduce the incidence of cardiovascular events like heart attack and stroke. This review synthesizes evidence on aspirin
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Cardiovascular diseases, including myocardial infarction and stroke, cause significant mortality in the UK.
- Many patients experiencing these events have pre-existing vascular disease or risk factors like hypertension and diabetes.
- Aspirin's antiplatelet properties have been known for 30 years, prompting extensive research into its cardioprotective effects.
Purpose of the Study:
- To review existing randomized clinical trial evidence on the efficacy of aspirin and other antiplatelet agents.
- To update conclusions regarding the role of aspirin in preventing stroke, myocardial infarction, and unstable angina.
- To advocate for the broader application of aspirin in specific high-risk patient populations.
Main Methods:
- Systematic review and meta-analysis of randomized clinical trials evaluating antiplatelet agents.
- Analysis of evidence focusing on cardiovascular morbidity and mortality outcomes.
- Synthesis of data to inform clinical recommendations for aspirin use.
Main Results:
- Evidence supports the use of aspirin in reducing the risk of recurrent cardiovascular events.
- Specific patient groups identified as high-risk benefit significantly from aspirin therapy.
- The review consolidates findings on aspirin's efficacy across stroke, myocardial infarction, and unstable angina.
Conclusions:
- Aspirin should be widely prescribed to mitigate cardiovascular morbidity and mortality in selected high-risk individuals.
- The antiplatelet benefits of aspirin are well-established for primary and secondary cardiovascular prevention.
- Continued research and clinical application are warranted to optimize aspirin use in cardiovascular disease management.
Abstract:
Each year in the United Kingdom about 250,000 people die from acute myocardial infarction, other ischaemic heart disease or stroke. Many will already have evidence of established vascular disease that predisposes to such an event--such as angina, peripheral vascular disease, atrial fibrillation, transient ischaemic attacks or a previous myocardial infarction or stroke. Others will have risk factors such as hypertension, diabetes mellitus or hyperlipidaemia, but the stroke or heart attack is the first evidence of established vascular disease. Aspirin was first discovered to have antiplatelet properties 30 years ago and since then many randomised clinical trials have sought to determine whether it (or other antiplatelet agents) can protect patients from heart attack or stroke. In this article we review the evidence and update our earlier conclusions on stroke, myocardial infarction, and unstable angina, arguing that aspirin should be widely used to reduce cardiovascular morbidity and mortality in certain high-risk patients.